Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Semin Oncol Nurs. 2024 Aug;40(4):151681. doi: 10.1016/j.soncn.2024.151681. Epub 2024 Jun 29.
Peripherally inserted central catheters are commonly used in cancer patients and provide vascular access for the administration of chemotherapy, antibiotics, or parenteral nutrition. Besides many advantages, they represent a source of possible complications such as catheter related blood stream infection, catheter occlusion, or thrombosis. In this study, the catheter-related complication rate between oncologic and non-oncologic patients was compared.
This retrospective cohort-study included 411 patients who underwent their first catheter placement at the Vienna General Hospital-Medical University of Vienna from January 2013 to June 2018. Patient demographics and catheter-related parameters were collected and statistically analyzed using a competing risk model.
Mean catheter dwell time was 27.75 days. The overall complication rate was 7.54% (2.72 per 1000 catheter days). Underlying malignant disease (hazard ratio: 0.351, 95% confidence interval [CI]: 0.133-0.929, P = .035) and chemotherapy administration (hazard ratio: 2.837, 95% CI: 1.088-7.394, P = .033) were significantly associated with the occurrence of any kind of complication. Catheter related blood stream infection was observed among 11 (2.68%) patients and again significantly associated with chemotherapy administration (hazard ratio: 4.545, 95% CI: 1.178-17.539; P = .028). Thrombosis was found in 7 (1.70%) patients and occlusion in 13 (3.16%) cases.
Choice of venous access is an interdisciplinary decision with emphasis on patient participation. In oncologic patients, our data suggests that the benefits of peripherally inserted central catheters regarding costs, invasiveness, and accessibility might be outweighed by the higher rate of complications associated with the device. This becomes even more important in a community care setting, where standardized handling procedures and patient education play a pivotal role in device safety.
外周中心静脉置管(PICC)常用于癌症患者,为化疗、抗生素或肠外营养的输注提供血管通路。除了许多优点外,它还可能导致一些并发症,如导管相关性血流感染、导管堵塞或血栓形成。本研究比较了肿瘤患者和非肿瘤患者的导管相关并发症发生率。
本回顾性队列研究纳入了 2013 年 1 月至 2018 年 6 月期间在维也纳综合医院-维也纳医科大学首次置管的 411 例患者。收集患者人口统计学和导管相关参数,并使用竞争风险模型进行统计学分析。
平均导管留置时间为 27.75 天。总体并发症发生率为 7.54%(每 1000 导管日 2.72 例)。基础恶性疾病(危险比:0.351,95%置信区间 [CI]:0.133-0.929,P=0.035)和化疗给药(危险比:2.837,95%CI:1.088-7.394,P=0.033)与任何类型并发症的发生显著相关。11 例(2.68%)患者发生导管相关性血流感染,再次与化疗给药显著相关(危险比:4.545,95%CI:1.178-17.539;P=0.028)。7 例(1.70%)患者发生血栓形成,13 例(3.16%)患者发生导管堵塞。
静脉通路的选择是一个跨学科的决策,强调患者的参与。在肿瘤患者中,我们的数据表明,外周中心静脉置管在成本、侵袭性和可及性方面的益处可能因与该设备相关的更高并发症发生率而被抵消。在社区护理环境中,这一点变得更加重要,在这种环境中,标准化的处理程序和患者教育在设备安全性方面发挥着关键作用。